U.S. Pharma bggie Novavax said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an agreement with Serum Institute of India.
In August, Novavax signed a deal with Serum Institute, the world's largest producer of vaccines, to produce a minimum of one billion doses of its vaccine candidate, when approved, for low and middle-income countries and India.
As part of the expanded agreement, Serum Institute will also manufacture the antigen component of the vaccine, dubbed NVX-CoV2373, which Novavax said will bring its manufacturing capacity to over two billion doses by mid-2021.
Novavax's vaccine is currently in mid-stage trials after an early-stage study showed it produced high levels of antibodies against the novel coronavirus. The company plans to begin late-stage trials in the third quarter.
The company is also preparing to deliver 100 million doses to the United States by January after it was awarded $1.6 billion for its potential vaccine, and has also signed supply agreements with Canada and Japan.